| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.45 | 53.21 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 11.82B | 44.08 | 25.05 | 18.49% | 29.63% | 31.37% | 5.36% | 0.09 |
| INBXInhibrx Biosciences, Inc. | 1.07B | 73.28 | 0.63 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.24B | 6.55 | -3.10 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.38B | 7.94 | -3.36 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 987.53M | 10.14 | -5.54 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.07B | 18.72 | -7.20 | 49.59% | -46.83% | -27.21% | 0.18 | |
| TNGXTango Therapeutics, Inc. | 1.41B | 10.44 | -8.77 | 15.17% | -151.15% | -62.81% | 0.18 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 82.65M | 3.03M | 1.38M | 25.55M | 10.01M |
| Revenue Growth % | - | - | - | -0.96% | -0.54% | 17.5% | -0.61% |
| Cost of Goods Sold | 2.15M | 2.85M | 3.55M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | 0.04% | - | - | - | - |
| Gross Profit | -2.15M | -2.85M | 79.11M | 3.03M | 1.38M | 25.55M | 10.01M |
| Gross Margin % | - | - | 0.96% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | -0.32% | 28.8% | -0.96% | -0.54% | 17.5% | -0.61% |
| Operating Expenses | 49.89M | 84.05M | 134.9M | 367.73M | 300.66M | 398.55M | 382.48M |
| OpEx % of Revenue | - | - | 1.63% | 121.4% | 217.71% | 15.6% | 38.22% |
| Selling, General & Admin | 8.86M | 13.74M | 38.59M | 57.39M | 65.98M | 74.95M | 76.59M |
| SG&A % of Revenue | - | - | 0.47% | 18.95% | 47.78% | 2.93% | 7.65% |
| Research & Development | 41.03M | 70.31M | 99.86M | 172.65M | 246.35M | 330.02M | 319.09M |
| R&D % of Revenue | - | - | 1.21% | 57% | 178.39% | 12.92% | 31.89% |
| Other Operating Expenses | -9K | 0 | -3.55M | 137.69M | -11.68M | -6.42M | -13.21M |
| Operating Income | -49.89M | -84.05M | -55.8M | -364.7M | -299.27M | -373M | -372.47M |
| Operating Margin % | - | - | -0.68% | -120.4% | -216.71% | -14.6% | -37.22% |
| Operating Income Growth % | - | -0.68% | 0.34% | -5.54% | 0.18% | -0.25% | 0% |
| EBITDA | -47.73M | -81.2M | -52.25M | -360.77M | -295.14M | -367.73M | -367M |
| EBITDA Margin % | - | - | -0.63% | -119.11% | -213.72% | -14.39% | -36.67% |
| EBITDA Growth % | - | -0.7% | 0.36% | -5.91% | 0.18% | -0.25% | 0% |
| D&A (Non-Cash Add-back) | 2.15M | 2.85M | 3.55M | 3.92M | 4.13M | 5.27M | 5.46M |
| EBIT | -48.78M | -84.05M | -55.8M | -227.01M | -310.95M | -379.42M | -385.67M |
| Net Interest Income | 0 | 8.8M | 3.4M | 830K | 8.79M | 31.05M | 34.75M |
| Interest Income | 1.11M | 8.8M | 3.4M | 830K | 8.79M | 31.05M | 34.75M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.1M | 8.74M | 3.38M | 826K | 8.77M | 31.03M | 34.76M |
| Pretax Income | -48.78M | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M |
| Pretax Margin % | - | - | -0.63% | -120.13% | -210.36% | -13.39% | -33.75% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 0.88% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -48.78M | -66.5M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M |
| Net Margin % | - | - | -0.63% | -120.13% | -210.36% | -13.39% | -33.75% |
| Net Income Growth % | - | -0.36% | 0.21% | -5.94% | 0.2% | -0.18% | 0.01% |
| Net Income (Continuing) | -48.78M | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -19.63 | -15.53 | -2.56 | -3.82 | -2.59 | -2.79 | -2.36 |
| EPS Growth % | - | 0.21% | 0.84% | -0.49% | 0.32% | -0.08% | 0.15% |
| EPS (Basic) | -19.63 | -15.53 | -2.56 | -3.82 | -2.59 | -2.79 | -2.36 |
| Diluted Shares Outstanding | 2.49M | 4.28M | 90.19M | 95.14M | 112.23M | 122.58M | 142.87M |
| Basic Shares Outstanding | 2.49M | 4.28M | 90.05M | 95.14M | 112.23M | 122.58M | 142.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 424.1M | 360.54M | 770.1M | 976.24M | 1.02B | 770.1M | 809.2M |
| Cash & Short-Term Investments | 421.5M | 355.82M | 678.06M | 958.07M | 998.92M | 750.09M | 781.32M |
| Cash Only | 421.5M | 41.95M | 447.65M | 280.12M | 998.92M | 143.74M | 124.29M |
| Short-Term Investments | 0 | 313.86M | 230.41M | 677.95M | 0 | 606.35M | 657.04M |
| Accounts Receivable | 0 | 0 | 82.65M | 4.94M | 5.22M | 0 | 0 |
| Days Sales Outstanding | - | - | 365 | 595.28 | 1.38K | - | - |
| Inventory | 0 | 0 | 0 | 0 | 12.11M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 1.76M | 3.26M | 3.31M | 10.53M |
| Total Non-Current Assets | 4.51M | 32.53M | 29.73M | 32.2M | 80.27M | 73.88M | 62.09M |
| Property, Plant & Equipment | 3.63M | 31.65M | 28.83M | 27.32M | 75.39M | 68.87M | 57.67M |
| Fixed Asset Turnover | - | - | 2.87x | 0.11x | 0.02x | 0.37x | 0.17x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 2.3M | 2.3M | 2.3M |
| Long-Term Investments | 878K | 0 | 0 | 0 | 2.58M | 2.71M | 0 |
| Other Non-Current Assets | 0 | 878K | 900K | 2.58M | 2.58M | 0 | 2.12M |
| Total Assets | 428.61M | 393.07M | 799.83M | 1.01B | 1.1B | 843.98M | 871.3M |
| Asset Turnover | - | - | 0.10x | 0.00x | 0.00x | 0.03x | 0.01x |
| Asset Growth % | - | -0.08% | 1.03% | 0.26% | 0.09% | -0.23% | 0.03% |
| Total Current Liabilities | 6.87M | 11.99M | 13.63M | 24.32M | 63.71M | 30.27M | 50.73M |
| Accounts Payable | 4.71M | 6.99M | 6.35M | 8.28M | 10.58M | 9.21M | 14.1M |
| Days Payables Outstanding | 797.27 | 896.91 | 653.17 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 0 | 0 | 248K | 0 | 0 | 1000K |
| Other Current Liabilities | 118K | 333K | 197K | 989K | 26.15M | 1.91M | 2.1M |
| Current Ratio | 61.78x | 30.08x | 56.49x | 40.14x | 16.00x | 25.44x | 15.95x |
| Quick Ratio | 61.78x | 30.08x | 56.49x | 40.14x | 15.81x | 25.44x | 15.95x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 532.67M | 561.52M | 22.9M | 86.31M | 85.84M | 61.71M | 42.77M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 23.58M | 22.9M | 21.06M | 53.47M | 48.5M | 42.77M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 532.67M | 537.94M | 3K | 65.26M | 32.38M | 13.21M | 0 |
| Total Liabilities | 539.54M | 573.51M | 36.54M | 110.64M | 149.55M | 91.98M | 93.5M |
| Total Debt | 178K | 24.83M | 24.42M | 22.9M | 57.74M | 53.47M | 48.5M |
| Net Debt | -421.33M | -17.12M | -423.22M | -257.22M | -941.17M | -90.27M | -75.78M |
| Debt / Equity | - | - | 0.03x | 0.03x | 0.06x | 0.07x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -110.93M | -180.44M | 763.29M | 897.81M | 950.22M | 752M | 777.79M |
| Equity Growth % | - | -0.63% | 5.23% | 0.18% | 0.06% | -0.21% | 0.03% |
| Book Value per Share | -44.64 | -42.15 | 8.46 | 9.44 | 8.47 | 6.13 | 5.44 |
| Total Shareholders' Equity | -110.93M | -180.44M | 763.29M | 897.81M | 950.22M | 752M | 777.79M |
| Common Stock | 3K | 4K | 90K | 109K | 121K | 127K | 168K |
| Retained Earnings | -114.18M | -189.48M | -404.23M | -768.1M | -1.06B | -1.4B | -1.74B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.65M | 325K | 64K | -1.09M | -10.42M | -196K | -991K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -44.13M | -66.13M | -102.49M | -74.41M | -229.49M | -300.32M | -249.11M |
| Operating CF Margin % | - | - | -1.24% | -24.56% | -166.18% | -11.76% | -24.89% |
| Operating CF Growth % | - | -0.5% | -0.55% | 0.27% | -2.08% | -0.31% | 0.17% |
| Net Income | -48.78M | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M |
| Depreciation & Amortization | 2.15M | 2.85M | 3.55M | 3.92M | 4.13M | 5.27M | 5.46M |
| Stock-Based Compensation | 2.89M | 4.46M | 31.96M | 48.45M | 56.14M | 86.03M | 94.14M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 9K | -2.44M | -416K | 139.74M | -10.49M | -17.18M | -25.62M |
| Working Capital Changes | -400K | 4.31M | -85.17M | 97.34M | 11.25M | -32.46M | 14.62M |
| Change in Receivables | 0 | 0 | -75M | 77.79M | 97K | 5.22M | 0 |
| Change in Inventory | 0 | 0 | -10.33M | 0 | 0 | 0 | 0 |
| Change in Payables | 1.23M | 3M | -410K | 930K | 1.99M | -2.39M | 0 |
| Cash from Investing | -1.68M | -319.02M | 81.67M | -479.51M | -188.75M | 257.63M | -41.08M |
| Capital Expenditures | -1.69M | -8M | -1.93M | -3.47M | -9.06M | -4.13M | -2.02M |
| CapEx % of Revenue | - | - | 0.02% | 1.15% | 6.56% | 0.16% | 0.2% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 7K | 20K | 83.6M | 0 | -179.68M | 0 | 0 |
| Cash from Financing | 394.97M | 5.61M | 426.51M | 388.09M | 289.91M | 34.75M | 270.15M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 717K | 613K | 1.22M | 5.88M | 5.17M | 4.47M | 4.26M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -45.82M | -74.14M | -104.42M | -77.88M | -238.55M | -304.44M | -251.13M |
| FCF Margin % | - | - | -1.26% | -25.71% | -172.74% | -11.92% | -25.09% |
| FCF Growth % | - | -0.62% | -0.41% | 0.25% | -2.06% | -0.28% | 0.18% |
| FCF per Share | -18.44 | -17.32 | -1.16 | -0.82 | -2.13 | -2.48 | -1.76 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.99x | 1.96x | 0.20x | 0.79x | 0.88x | 0.74x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -17.98% | -43.81% | -31.44% | -40.18% | -44.15% |
| Return on Invested Capital (ROIC) | - | - | -58.73% | -55.78% | -69.1% | -83.41% | -40.97% |
| Gross Margin | - | - | 95.71% | 100% | 100% | 100% | 100% |
| Net Margin | - | - | -63.41% | -12012.94% | -21036.13% | -1338.66% | -3374.72% |
| Debt / Equity | - | - | 0.03x | 0.03x | 0.06x | 0.07x | 0.06x |
| FCF Conversion | 0.90x | 0.99x | 1.96x | 0.20x | 0.79x | 0.88x | 0.74x |
| Revenue Growth | - | - | - | -96.34% | -54.41% | 1749.82% | -60.83% |
Relay Therapeutics, Inc. (RLAY) reported $11.1M in revenue for fiscal year 2024.
Relay Therapeutics, Inc. (RLAY) saw revenue decline by 60.8% over the past year.
Relay Therapeutics, Inc. (RLAY) reported a net loss of $297.6M for fiscal year 2024.
Relay Therapeutics, Inc. (RLAY) has a return on equity (ROE) of -44.2%. Negative ROE indicates the company is unprofitable.
Relay Therapeutics, Inc. (RLAY) had negative free cash flow of $248.9M in fiscal year 2024, likely due to heavy capital investments.